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Hepatitis C virus (HCV) infection unfavorably affects the survival of both renal patients undergoing hemodialysis and renal
transplant recipients. In this subset of patients, the effectiveness and safety of different combinations of interferon-free direct-acting
antiviral agents (DAAs) have been analyzed in several small studies. Despite fragmentary, the available data demonstrate that DAA
treatment is safe and effective in eradicatingHCV infection, with a sustained virologic response (SVR) rates nearly 95% andwithout
an increased risk of allograft rejection.This review article analyzes the results of most published studies on this topic to favor more
in-depth knowledge of the readers on the subject. We suggest, however, perseverating in this update as the optimal DAA regimen
may not be proposed yet, because of the expected arrival of newer DAAs and of the lack of data from large multicenter randomized
controlled trials.
1. Introduction
Hepatitis C virus (HCV) infection affects nearly 150 million
people worldwide and more than 350,000 people die each
year of HCV-related diseases [1–7]. In the adult popula-
tion, HCV infection is associated with an increased risk of
developing chronic kidney disease [8] and the prevalence
of HCV infection is greater among patients with chronic
kidney disease (1.8% -8%) than in the general population
(0.5-4%), especially in those undergoing hemodialysis and
in renal allograft recipients [9–22]. In these patients, HCV
infection is a risk factor for other comorbidities [9, 23, 24]. In
fact, in renal allograft recipients, HCV has been found to be
associated with posttransplant proteinuria, with an increased
risk of new-onset diabetes possibly leading to cardiovascular
diseases and malignancies, and with allograft loss, infections,
and death [9, 12, 25–40]. Therefore, it is highly desirable
to treat HCV infection before or after renal transplant to
eliminate at the same time both HCV infection and the risk
of complications [40–50].
Interferon-based regimens had been the backbone of
HCV treatment for kidney transplant recipients until 2014, a
therapeutic approach limited by the relatively low efficacy in
achieving viral eradication, poor tolerability [51, 52], and the
obligation to use it only before transplant because of the high
risk of inducing immune stimulation and allograft rejection
[53–55].
The first-generation direct-acting antivirals (DAAs) pro-
tease inhibitors telaprevir and boceprevir present a similar
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limitation because their efficacy depends on the coadminis-
tration of interferon [56–63]. Instead, the currently available
new generation DAAs, associated with a greater sustained
viral response (SVR) and with a good safety profiles, have
strongly improved the treatment of chronic HCV infection
even in renal patients [64–68]. HCV eradication is testified by
the achievement of a sustained virologic response 12 (SVR12),
highlighted by the undetectability of serumHCVRNAwithin
the 12th week of treatment and throughout a subsequent
follow-up of 12 weeks.
A clear example of the efficacy of DAAs in eradicating
HCV infection in patients with chronic kidney diseases
(CKD) is offered by the C-SURFFER study, a multicenter,
double-blind, randomized study where 224 patients with
HCV GT1 infection and CKD stages 4 or 5 were randomly
assigned to an “immediate treatment group” receiving gra-
zoprevir and elbasvir (n=111) for 12 weeks or to a “deferred
treatment” group treated with the same schedule (n=113) 16
weeks later. Most of patients were haemodialysis dependent;
half of them had HCV genotype 1a infection, 80% were HCV
treatment naı¨ve, and 6% had liver cirrhosis. SVR rates in the
“immediate treatment” and “deferred treatment” groupswere
99% and 98, respectively [69].
There are four classes of direct-acting antiviral drugs that
combine the attack on more than one HCV life cycle goal: (1)
NS3/4A protease inhibitors (galexos, grazoprevir, sunvepra,
glecaprevir, paritaprevir, and voxilaprevir); (2) the nucleoside
and nucleotide NS5B polymerase inhibitors (sofosbuvir);
(3) NS5A inhibitors (ombitasvir, pibrentasvir, daclatasvir,
elbasvir, ledipasvir, ombitasvir, and velpatasvir); and (4)
nonnucleoside NS5B polymerase inhibitors (dasabuvir).
General symptoms (adverse events, fatigue, nausea, dizzi-
ness, or headache) associated with DAA treatment in kidney
transplant recipients have been reported in nearly 40% of
treated patients, whereas severe adverse events (i.e., anemia,
portal vein thrombosis, or pneumonia) are infrequent events
(around 1% of treated patients) [70].
Glomerular disease after DAAs has been also described.
Lubetzky et al. [71] reported no significant change in
glomerular filtration rate (GFR) before or after therapy, but 3
patients showed a decrease ofGFR to less than 20 and 19.3%of
31 patients had worsening proteinuria during or shortly after
therapy. Besides, patients with a proteinuria over 500 mg/g
before treatment showed an increased value during treatment
more frequently than those with initial values lower than 500
mg/g (P < 0.001) [71].
In this review article we analyze the data from several
real-life studies on the feasibility, effectiveness, and tolera-
bility of DAA therapies for kidney transplant recipients. The
experience of most single studies is limited, prevalently by
the low number of patients examined, but a comprehensive
analysis of the available data can give useful indications to the
readers [68–75].
Episodes of reactivation of an indolent (open or
occult) Hepatitis B virus (HBV) infection in patients with
HBV/HCV-related chronic hepatitis during or after a
successful DAA therapy have been documented [76]. HBV
reactivation of open or occult HBV infection has been
observed even in kidney-transplant recipients with HBV/
HCV-related chronic hepatitis after a SVR had been achieved
with DAA treatment. [77].
2. DAA Agents for Treatment of HCV Infection
in Patients with Chronic Kidney Disease
In HCV-related liver diseases, the combined use of two
or more second-generation DAAs allows the eradication of
HCV infection in nearly 95% of treated patients [78–83], a
percentage obtained even in liver transplant recipients [64,
66].
The knowledge on HCV eradication with DAA therapy
in HCV-positive renal recipients or in those on a waiting list
for renal transplantation is fragmentary, but the published
data are highly promising. For HCV-positive patients in
the wait list for kidney transplantation the first decision is
whether to treat them before or after transplantation. For
HCV patients with mild or moderate hepatic fibrosis who
have a living kidney donor, treatment with DAA has been
suggested prior to kidney transplantation [55, 67]. For HCV-
positive patients who do not have a living donor and are
at risk of progression to a more severe liver disease it has
been suggested to perform kidney transplantation and to
treat them with DAAs soon after, a decision that allows
receiving a kidney from an HCV-positive donor [68] and
reducing wait time for transplantation dramatically. Indeed,
it has been recently reported that patients who accepted to
be transplanted with anHCV-positive kidney, compared with
those who have reclaimed an HCV-negative donor kidney
transplant, have lower average waiting (469 vs 856 days) [67].
For an exhaustive analysis, it should be also considered that,
due to the shortage of transplantable kidneys, in 2014, of
98, 956 patients on waiting list for kidney transplantation in
the USA, more than 8,000 (8%) had died or were removed
from the list due to worsening in clinical conditions [69, 75,
78].
All this considered, it is commonly accepted that HCV-
infected transplant candidates may receive a kidney from
an HCV-positive donor. This eventuality had occurred in
about 2500 donations in the USA between 2005 and 2014
[73]; otherwise these kidneys would have been discarded.The
transplantation of HCV-infected kidneys in HCV-infected
patients, in addition to reducing waiting times [82], expands
the pool of usable kidneys. The largest series [83] of renal
transplants performed under these conditions demonstrated
a 5-year and 10-year equivalent patient survival (p= 0.25)
compared to those who received a kidney from an HCV-
negative donor. Considering the persistent shortage of kid-
neys that can be transplanted, it has been also proposed
to transplant HCV- positive kidneys into HCV-negative
recipients and to initiate treatment with DAA immediately
after transplantation and before a liver disease might develop.
At present, no valid recommendation comes from
prospective trials, but several studies, prevalently small and
from single clinical centers, provide useful information on the
effectiveness and tolerability of different DAAs combination
regimens in HCV-positive transplant recipients.
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In a retrospective, multicentric study Ferna´ndez et al [84]
observed a SVR12 in 98% of 103 kidney transplant recipients
treated with DAAs (sofosbuvir plus ledipasvir in 59 and
sofosbuvir plus daclatasvir in 18). Ribavirin was used in 1%
of cases. Of these 103 patients, therapy was administered for
12 weeks in 72, for 24 weeks in 29, and for 8 weeks in two.
There were three episodes of acute humoral graft rejection.
No patient discontinued therapy due to adverse events, but 57
patients required immunosuppression dose adjustment. SVR
was achieved by 98% of patients receiving DAAs alone and
97.6% of those receiving DAAs plus RBV, by 97% of those
receiving 12 weeks of therapy, and 100% of those treated for
24 weeks. The presence of cirrhosis did not influence the
response to treatment [84].
Lin et al. [85] treated 6 HCV-positive kidney recipients
with a 12-week sofosbuvir/daclatasvir treatment (4 of 6 with
HCV genotype 1b). HCV RNA was undetectable at week 4
and a SVR12 was obtained in all cases. Half dose of sofosbuvir
was used in two patients with creatinine elevation. Treatment
was well tolerated, and no adverse reaction had occurred.
Eisenberger et al. [83] assessed the efficacy and safety of
8- or 12-week combination of sofosbuvir plus ledipasvir in 15
kidney recipients with HCV infection (genotypes 1a, 1b, or 4).
All patients achieved a SVR12, had a stable renal transplant
function, and did not develop serious adverse events. A dose
adjustment for tacrolimus was necessary in some cases. The
authors concluded that the treatment was safe and effective.
Kamar et al. [66] treated 25 kidney transplant recipients
with HCV infection with different sofosbuvir-based regi-
mens. A rapid SVR, defined by undetectable viremia after 4
weeks of DAA therapy, was obtained in 22 (88%) cases and
SVR12 in all. Treatments were well tolerated, and no adverse
event had occurred, apart from a decrease in calcineurin
inhibitor levels after HCV clearance. Lubetzky et al. [71]
performed a retrospective cohort analysis of 31 HCV-positive
patients who underwent kidney transplantation and received
DAA therapy. The combination of sofosbuvir/ledipasvir was
the most commonly used and 30 out of the 31 (97%) achieved
SVR12; all patients showed a satisfactory allograft function.
Six (19.3%) out of the 31 showed an increased proteinuria
during or shortly after DAA therapy. The authors concluded
that DAA therapy is safe and effective in HCV-positive
kidney recipients and that patients with proteinuria should
be monitored closely [71].
Bhamidimarri et al. [86] described 25HCVpatients in the
end-stage kidney disease, transplanted with a kidney from an
anti-HCV-positive deceased donor and treated with DAAs in
the early post-transplant period (median 125 days). Of these
25, 24 (96%) achieved a SVR12. Tacrolimus dose adjustments
were required in 13 patients.
Sawinski et al. [87] used 4 different DAA regimens to treat
43 renal transplant recipients; all of them obtained SVR 12
independently from the origin of the allograft (from anHCV-
positive or -negative donor) and none of them showed a seri-
ous adverse reaction. A calcineurin inhibitor dose adjustment
during treatment was applied in nearly half treated patients.
Noteworthy, the waiting time to transplantation was longer
in patients transplanted with a kidney from anHCV-negative
donor than in those transplantedwith anHCV-positive organ
(969 versus 485 days) [84].
Colombo et al. [88] carried out a randomized, phase 2,
open-label multicenter study including 114 kidney transplant
recipients with HCV infection (HCV genotypes 1 or 4) infec-
tion andwith a filtration rate (eGFR) of 40mL/min or greater.
These 144 were randomly assigned 1:1 to receive ledipasvir
90 mg and sofosbuvir 400 mg either for 12 or for 24 weeks;
91% had HCV genotype 1 infection and 15% compensated
cirrhosis. A SVR12 was achieved by all treated patients, with
no regard to the duration of treatment. Treatment was well
tolerated in most cases, but serious adverse events occurred
in 13 (11%) patients. The authors concluded that treatment
with ledipasvir/sofosbuvir is effective ad shows an acceptable
safety profile in HCV-positive kidney transplant recipients.
Londono et al. [89] described 103 HCV-positive kidney
transplant recipients, 15% with cirrhosis, treated with DAAs,
prevalently sofosbuvir/ledipasvir (n=59, 57%) or sofosbu-
vir/daclatasvir (n=18, 17%). Ribavirin was associated with
DAAs in nearly half patients. The SVR12 rate was 98%. A
grade 2 or 3 anaemia developed in 14 (33%) patients treated
with ribavirin and in 9 (15%) untreated (p=0.03). No patient
discontinued therapy because of an adverse event, but an
adjustment of the dose of immunosuppressive drugs was
required in nearly half of them. A mild allograft dysfunction
occurred only in cirrhotic patients. An acute humoral graft
rejection occurred in 3 patients. The authors concluded
that DAA therapy was highly efficacious and safe in kidney
transplant recipients.
Gallegos-Orozco et al. [90] described 8 HCV-positive
kidney recipients (7 with an HCV-positive kidney and one
with an HCV-negative kidney), treated three to six months
after transplantation with DDA therapy according to HCV
genotype and their prior treatment experience: all of them
had functioning kidney grafts and achieved SVR12. The
authors concluded that HCV-positive patients can success-
fully receive an HCV-positive kidney from an HCV-positive
donor, with a substantial reduction of time on the wait list.
Durand et al. [91] conducted a nonrandomized open
label study to evaluate the tolerability and efficacy of DAA
treatment given before and after kidney transplantation to
10 non-HCV infected kidney recipients receiving an HCV-
infected organ. All recipients transplanted with an HCV-
positive genotype 1 infected kidney were treated with gra-
zoprevir, 100 mg, and elbasvir, 50 mg, immediately before
transplantation and for 12 weeks after transplantation, while
for the recipients of a kidney from a donor infected withHCV
genotypes 2 or 3 sofosbuvir, 400mg,was added to grazoprevir
and elbasvir in a triple therapy during the 12-week treatment
period after transplantation. All patients achieved a SVR12
and no treatment-related adverse events had occurred [91].
Goldberg et al. [92] evaluated safety and efficacy of
kidney transplantation from HCV genotype 1 donors into
HCV-negative recipients, followed by elbasvir/grazoprevir
treatment in an open-label, single-group, pilot trial. Patients
undergoing dialysis who had long awaited kidney trans-
plant have been included in the study and transplanted.
Ten patients received HCV-infected kidneys, became HCV
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RNA positive beginning from the day 3 after transplan-
tation, received a 12-week elbasvir/grazoprevir combina-
tion, and achieved SVR12. The authors concluded that the
transplantation of HCV genotype 1 infected kidneys into
HCV-negative recipients, followed by the administration of
elbasvir/grazoprevir, ensures an excellent allograft and the
healing of the provoked HCV infection [92].
3. Strategies, Future Expectation, and
Conclusion on the DAA Treatment of Renal
Recipients with HCV Infection
The DAA regimens for HCV-positive renal transplant recip-
ients should be adequate to HCV genotype, the entity of
liver disease, the quality of posttransplant renal function,
and the immunosuppressive drugs administered. A close
monitoring of renal function during theDAAadministration,
with adjustment of DAA doses to the patients’ eGFR, and a
careful observation of a possible onset of drug to drag interac-
tions, with adjustment of doses of immunosuppressive drugs,
were recommended. For example, sofosbuvir-based DAA
regimens may induce renal adverse events in patients with
reduced renal function, particularly in those in an end-stage
renal disease (ESRD) [93, 94], while the administration of the
combination therapy of dasabuvir, ombitasvir, paritaprevir,
and ritonavir [95] may lead to drug to drug interactions in
patients under a CNI-based immunosuppressive therapy.
Calcineurin inhibitors (tacrolimus and ciclosporin)
and the mechanized target of rapamycin inhibitors (ever-
olimus and sirolimus), used as immunosuppressants in
patients undergoing renal transplantation, are substrates of
cytochrome P450 and therefore the possible interactions
between these drugs and DAAs should always be taken into
consideration [58, 96–98]. During the DAA treatment of
HCV-positive kidney recipients, the decrease in HCV load
is frequently followed by a decrease in tacrolimus levels that
often requires dose adjustment. This possibility has been
well demonstrated by Kamar et al. [66] in renal transplant
patients treated with sofosbuvir in various combinations
with other antiviral drugs. Although no episodes of rejection
or deterioration of the transplanted organ had occurred,
the data highlight the need for careful monitoring of
immunosuppressive drug levels and dose adjustment [66].
The optimal timing ofHCV therapy (pretransplant versus
posttransplant) in HCV-positive transplant recipients is topic
of debate. Several studies have shown that the wait times
for kidney transplantation from HCV-positive donors are
significantly shorter than those for kidneys from uninfected
donors. These considerations support the use of all kidneys
available for transplantation in HCV-positive patients, both
HCV-negative and HCV-positive.
The Kidney Disease Improving Global Outcomes guide-
lines currently recommend treating with DAAs the HCV
RNA positive candidates for renal transplant while still
in dialysis [41], since once SVR12 has been achieved, a
relapse after renal transplant seems unlikely [99]. However,
once SVR12 has been achieved with DAA treatment before
transplantation, the possibility to receive a renal graft from
an HCV-positive donor is lost, together with the benefit of
shortening the length of dialysis and of wait time in the kid-
ney transplantation list and with the possibility of reducing
comorbidities (i.e., cardiovascular complications) [99, 100].
However, for HCV-positive patients with mild or moderate
hepatic fibrosis on a waiting list the high effectiveness of
the new DAAs has allowed starting treatment immediately
after transplantation [99, 100], a benefit balanced in some
cases by the risk of an acute renal injury due to the potential
interaction between DAAs and immunosuppressants. In this
regard it should also be considered that many of the current
DAAs require a creatinine clearance level of 30 ml/min
or greater because their main elimination route is renal
[58].
Because of the persistent shortage of kidneys that can
be transplanted, it has been proposed to transplant HCV-
positive kidneys into HCV-negative recipients and to initi-
ate treatment with DAA immediately after transplantation,
before the liver disease develops. However, although a few
preliminary studies have provided encouraging results, the
ethical implications of this procedure should be carefully
evaluated, since approximately 5% of patients may not obtain
SVR12 with DAA treatment; in some cases the donor HCV
genotype may be difficult to treat one (i.e., HCV genotype
3) and in very rare cases fibrosing cholestatic hepatitis may
develop after kidney transplantation.
4. Final Remarks
A careful assessment of the stage of liver disease should be
made including an accurate anamnesis, complete physical
examination, serial determinations of serum liver function
tests (serum levels of albumin, bilirubin and liver enzymes,
prothrombin time, and platelet count), upper abdominal
ultrasound examination, and endoscopic examination of the
upper intestinal tract in cirrhotic patients. Patients with
advanced fibrosis should be regularly revaluated.
The occurrence of reactivation of an indolent (open or
occult) Hepatitis B virus (HBV) infection in HBV/HCV
kidney-transplant recipients [77] during or after DAA [76]
should be prevented by a nucleoside/nucleotide analogue
prophylaxis in HBsAg-positive patients and early identified
by an accurate monitoring (ALT serum levels and HBsAg)
in HBsAg-negative/anti-HBc-positive patients [74]. In case
of HBV reactivation in HBsAg-negative/anti-HBc-positive
patients a treatment with nucleoside/nucleotide analogues
should be started.
Most DAA therapeutic regimens are practically restricted
to HCV genotypes 1 and 4, while HCV genotype 3 is
quite frequent and equally dangerous. This need will be
overcome by the newer pan-genotypic DAAs regimens (gle-
caprevir/pibrentasvir).
The optimal regimens to be applied either before or after
kidney transplantation may not be proposed yet, because
of the expected arrival of other newer DAAs and of results
from multicenter randomized controlled trials. Newer DAA
regimens requiring a shorter duration of treatment may also
accelerate the access to transplantation.
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The possibility to transplant HCV-positive kidneys into
HCV-negative recipients has been recently analyzed by the
American Society of Transplantation Consensus Conference
on HCV-positive donors and kidney transplantation. It has
been considered that the high level of safety and efficacy of
DAAs in eradicating HCV infection provides the opportunity
to explore their use in transplanting kidneys from HCV-
viremic patients into non-HCV-viremic recipients, a practice
that could save the life of numerous CKD patients with organ
failure. Although more research is needed before making a
final settlement on this topic, the consensus underlines the
need to guarantee the access to DAA therapy to the HCV-
negative recipients at the time they will receive a kidney from
an HCV-positive donor.
It has been also underlined that a living donor who
has cleared HCV infection after DAA treatment does not
transmit HCV infection to the kidney recipients [101–105].
Treating HCV infection before kidney transplantation
could be potentially advantageous, since eradicating HCV
would lead to better allograft and patient survival.
Ideally, patients with ESRD and HCV infection should
be comanaged by surgeons, nephrologists, and hepatologists
before and after transplantation.
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